What is Embark Veterinary?
Based in Boston, Massachusetts, Embark Veterinary operates at the intersection of biotechnology and consumer pet care. The company provides comprehensive DNA testing services for dogs, offering owners detailed insights into breed composition, health predispositions, and physical traits. Beyond its consumer-facing products, Embark utilizes the vast repository of genetic information collected to fuel large-scale research initiatives. This dual-model approach—combining a direct-to-consumer platform with a robust data-driven research engine—positions the company as a leader in the effort to help dogs lead longer, healthier lives through precision medicine.
How much funding has Embark Veterinary raised?
Embark Veterinary has raised a total of $91.3M across 4 funding rounds:
Other Financing Round
$1.8M
Other Financing Round
$4.5M
Series A
$10M
Series B
$75M
Other Financing Round (2016): $1.8M with participation from AGO Partners, Fabrice Grinda, and Slow Ventures
Other Financing Round (2017): $4.5M led by SV Angel, Anne Wojcicki, Founder Collective, and Section 32
Series A (2019): $10M supported by Freestyle Capital, Third Kind Venture Capital, Slow Ventures, FJ Labs, F-Prime Capital Partners, Section 32, and Anne Wojciciki
Series B (2021): $75M featuring F-Prime Capital Partners, Third Kind Venture Capital, Slow Ventures, SoftBank Group Corp, SV Angel, and Freestyle
Key Investors in Embark Veterinary
SoftBank Group Corp
SoftBank Group Corp. is a global technology holding company driving innovation across telecommunications, internet services, artificial intelligence, and clean energy technologies through its diverse portfolio and strategic investment platforms.
F-Prime Capital Partners
F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology for other companies.
SV Angel
SV Angel is a long-term investment firm dedicated to supporting founders in creating impactful businesses by providing essential resources, strategic insights, and a vast network to help companies scale.
What's next for Embark Veterinary?
Looking ahead, the recent infusion of capital is expected to accelerate Embark Veterinary's research and development pipeline. The company is likely to focus on enhancing its predictive health algorithms and expanding its database to include a broader range of canine genetic markers. As the firm matures, strategic priorities will likely shift toward integrating its findings into clinical veterinary practices, thereby bridging the gap between consumer genetic testing and professional veterinary diagnostics. Continued investment will be critical in maintaining its competitive edge as the industry moves toward more personalized, data-informed pet healthcare solutions.
See full Embark Veterinary company page
